Cellebrite DI Ltd

Cellebrite DI Ltd (CLBT) Stock Analysis

$12.000

+0.010 (+0.08%)At close

Loading chart…
High
12.130
Open
11.800
VWAP
11.98
Vol
1.33M
Mkt Cap
2.43B
Low
11.800
Amount
15.93M
EV/EBITDA, TTM
51.10

Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world.

AI analysis of Cellebrite DI Ltd (CLBT)

hold

Cellebrite DI Ltd is currently not a strong buy due to its recent performance and lowered guidance. The current price is $11.99, which is significantly below the analyst price target of $22 from DA Davidson, indicating potential upside. However, the company has faced challenges, including a 29.18% drop in stock price following a revenue guidance cut, which is a major risk. Additionally, the RSI is at 49.83, suggesting the stock is neither overbought nor oversold, indicating a wait-and-see approach may be prudent.

Valuation Metrics

The current forward P/E ratio for Cellebrite DI Ltd (CLBT) is 35.71, compared to its 5-year average forward P/E of 43.29.

Forward P/E

Fair
5Y Average P/E
43.29
Current P/E
35.71
Overvalued
63.17
Undervalued
23.42

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
30.35
Current EV/EBITDA
51.10
Overvalued
43.16
Undervalued
17.53

Forward P/S

Fair
5Y Average P/S
5.73
Current P/S
4.69
Overvalued
8.00
Undervalued
3.45

Alphio AI Price Scenarios for CLBT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CLBT

$24.00

Scenario price

B

Base

Base · 50%CLBT

$20.91

Scenario price

B

Bear

Bear · 25%CLBT

$20.21

Scenario price

Whales holding CLBT

G

Granahan Investment Management, LLC

+ HoldingCLBT

+15.20%

3M Return

P

Progeny 3, Inc.

+ HoldingCLBT

+3.63%

3M Return

V

Voss Capital, LP

+ HoldingCLBT

+2.81%

3M Return

P

Phoenix Investments & Finances Ltd

+ HoldingCLBT

-3.33%

3M Return

P

Portolan Capital Management, LLC

+ HoldingCLBT

-4.79%

3M Return

I

Investor AB (publ)

+ HoldingCLBT

-6.46%

3M Return

Events Timeline

2026-08-13 (ET)

16:30:00

Major Averages Rise as Oil Prices Fall

12:30:00

Cellebrite Shares Drop 31.8% to $10.40

12:00:00

Major Averages Rise as Oil Prices Fall

10:30:00

Cellebrite Shares Drop 35.7% to $9.80

07:30:00

Inseyets Reports Q2 Revenue of $131.1M, Below Expectations

News

CLBT FAQ — answered by Alphio AI

Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. It operates in the Technology sector.

Cellebrite DI Ltd is currently not a strong buy due to its recent performance and lowered guidance. The current price is $11.99, which is significantly below the analyst price target of $22 from DA Davidson, indicating potential upside. However, the company has faced challenges, including a 29.18% drop in stock price following a revenue guidance cut, which is a major risk. Additionally, the RSI is at 49.83, suggesting the stock is neither overbought nor oversold, indicating a wait-and-see approach may be prudent.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started